Americans fund most of the world’s drug research. Here’s how Trump can end that.

9 August 2018 - President Donald Trump recently released an ambitious, 44-page plan to drive down prescription drug prices. The ...

Read more →

Sesen Bio announces Vicinium granted fast track designation by FDA for treatment of non-muscle invasive bladder cancer

9 August 2018 - Sesen Bio today announced that the U.S. FDA has granted fast track designation to Vicinium for the ...

Read more →

Glenmark Pharmaceuticals announces FDA acceptance of the company's first new drug application for Ryaltris for patients with seasonal allergic rhinitis

7 August 2018 - The PDUFA target action date for completion of the FDA review is 21 March 2019. ...

Read more →

Genmab announces submission of U.S. & EU regulatory applications seeking approval of Darzalex (daratumumab) split dosing regimen

8 August 2018 - Applications seek to update prescribing information and summary of product characteristics. ...

Read more →

FDA approves treatment for two rare types of non-Hodgkin lymphoma

8 August 2018 - The U.S. FDA today approved Poteligeo (mogamulizumab-kpkc) injection for intravenous use for the treatment of adult patients ...

Read more →

FDA approves first generic drug under new pathway aimed at enhancing market competition for sole source drugs

8 August 2018 - The U.S. FDA today approved several strengths of potassium chloride oral solution as the first generic drugs ...

Read more →

The FDA is poised to approve the first-ever drug that mutes disease-causing genes

7 August 2018 - After a decades-long wait, the FDA is on the brink of approving a landmark rare disease ...

Read more →

Patient reported outcome measures in the FDA pilot compendium: meeting today’s standards for patient engagement in development?

7 August 2018 - In 2016, the FDA released a pilot clinical outcome assessment compendium intended to foster patient-focused drug development.  ...

Read more →

Nohla Therapeutics receives FDA fast track designation for dilanubicel for allogeneic cord blood transplant patients

6 August 2018 - Nohla Therapeutics today announced that the U.S. FDA has granted fast track designation to dilanubicel (NLA101) for ...

Read more →

FDA approves Orkambi (lumacaftor/ivacaftor) as first medicine to treat the underlying cause of cystic fibrosis for children ages 2-5 years with most common form of the disease

7 August 2018 - Approximately 1,300 people in the U.S. ages 2 through 5 years have two copies of the F508del ...

Read more →

Array Biopharma receives FDA breakthrough therapy designation for Braftovi in combination with Mektovi and cetuximab for BRAF V600E mutant metastatic colorectal cancer

7 August 2018 - Designation based on Phase 3 BEACON CRC safety lead-in data. ...

Read more →

Karyopharm completes rolling submission of new drug application to U.S. FDA for selinexor as a treatment for patients with penta-refractory multiple myeloma

6 August 2018 - Selinexor has received both orphan drug and fast track designations from the FDA for this indication. ...

Read more →

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

6 August 2018 - The U.S. FDA today issued new scientific recommendations aimed at encouraging more widespread innovation and development of ...

Read more →

Complete response letter issued for Remoxy

6 August 2018 - Pain Therapeutics today announced it had received a complete response letter from the U.S. FDA for its ...

Read more →

U.S. FDA grants fast track designation for BioCryst’s BCX7353

6 August 2018 - BioCryst Pharmaceuticals today announced that the Company has been granted fast track designation by the U.S. ...

Read more →